HLA class I expression on human cancer cells: Implications for effective immunotherapy

This publication has 64 references indexed in Scilit:

• Phase I Evaluation of Interleukin-2-Transfected Irradiated Allogeneic Melanoma for the Treatment of Metastatic Melanoma. University of Illinois at Chicago, Chicago, Illinois
  Human Gene Therapy, 1997
• Comparison of Natural Killer (NK) Sensitivities of Two Tumor Cell Lines Established from a Cancer Patient before and after Radiation Therapy
  Clinical Immunology and Immunopathology, 1997
• High frequency of altered HLA class I phenotypes in invasive breast carcinomas
  Human Immunology, 1996
• A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3
  European Journal of Immunology, 1994
• Cellular Mucins: Targets for Immunotherapy
  Critical Reviews in Immunology, 1994
• Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1
  Nature, 1993
• A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.
  The Journal of Experimental Medicine, 1992
• A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
  Science, 1991
• Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma
  New England Journal of Medicine, 1988
• IMMUNOLOGICAL DETERMINANTS OF POLYOMA VIRUS ONCOGENESIS
  The Journal of Experimental Medicine, 1962